StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.12−0.10 (-1.39%)

Close on Nov 19, 2026Market cap $367.54MP/E 13.7Yield –

Puma Biotechnology operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Puma Biotechnology's operating income for the twelve months ending Jun 30, 2026 was $30.44M, down 33.9% year over year. For fiscal 2025 it was $37.30M, up 20.5% from the year before. The highest annual figure on record is $37.30M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$37.30M+20.5%
FY2024Dec 31, 2024$30.97M-5.1%
FY2023Dec 31, 2023$32.64M+37.6%
FY2022Dec 31, 2022$23.72M+1738.8%
FY2021Dec 31, 2021$1.29M–
FY2020Dec 31, 2020-$30.40M–
FY2019Dec 31, 2019-$39.05M–
FY2018Dec 31, 2018-$94.66M–
FY2017Dec 31, 2017-$292.39M–
FY2016Dec 31, 2016-$276.60M–
FY2015Dec 31, 2015-$240.28M–
FY2014Dec 31, 2014-$142.28M–
FY2013Dec 31, 2013-$54.83M–
FY2012Dec 31, 2012-$74.45M–
FY2011Dec 31, 2011-$10.16M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$7.59M+14.3%
Q1 FY2026Mar 31, 2026-$3.83M-196.1%
Q4 FY2025Dec 31, 2025$17.11M+28.0%
Q3 FY2025Sep 30, 2025$9.57M-56.6%
Q2 FY2025Jun 30, 2025$6.64M–
Q1 FY2025Mar 31, 2025$3.98M–
Q4 FY2024Dec 31, 2024$13.37M-9.7%
Q3 FY2024Sep 30, 2024$22.08M+157.2%
Q2 FY2024Jun 30, 2024-$2.18M-144.5%
Q1 FY2024Mar 31, 2024-$2.30M-152.7%
Q4 FY2023Dec 31, 2023$14.80M+47.7%
Q3 FY2023Sep 30, 2023$8.59M+258.8%
Q2 FY2023Jun 30, 2023$4.89M-59.4%
Q1 FY2023Mar 31, 2023$4.37M–
Q4 FY2022Dec 31, 2022$10.02M+46.6%
Q3 FY2022Sep 30, 2022$2.39M–
Q2 FY2022Jun 30, 2022$12.06M–
Q1 FY2022Mar 31, 2022-$747.00K-103.7%
Q4 FY2021Dec 31, 2021$6.83M–
Q3 FY2021Sep 30, 2021-$8.95M–
Q2 FY2021Jun 30, 2021-$16.63M-333.3%
Q1 FY2021Mar 31, 2021$20.15M–
Q4 FY2020Dec 31, 2020-$11.15M–
Q3 FY2020Sep 30, 2020-$12.13M–
Q2 FY2020Jun 30, 2020$7.13M–
Q1 FY2020Mar 31, 2020-$14.25M-244.7%
Q4 FY2019Dec 31, 2019-$8.67M–
Q3 FY2019Sep 30, 2019-$14.45M–
Q2 FY2019Jun 30, 2019-$25.78M–
Q1 FY2019Mar 31, 2019$9.85M–
Q4 FY2018Dec 31, 2018-$18.54M–
Q3 FY2018Sep 30, 2018-$11.28M–
Q2 FY2018Jun 30, 2018-$41.44M–
Q1 FY2018Mar 31, 2018-$23.39M–
Q4 FY2017Dec 31, 2017-$63.57M–
Q3 FY2017Sep 30, 2017-$77.44M–
Q2 FY2017Jun 30, 2017-$78.18M–
Q1 FY2017Mar 31, 2017-$73.20M–
Q4 FY2016Dec 31, 2016-$72.87M–
Q3 FY2016Sep 30, 2016-$66.00M–

More Puma Biotechnology figures

See a number that looks wrong?